31 March 2008 -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received two separate approvals from the US Food & drug administration to market Bupropion Hydrochloride extended-release tablets (SR). Distribution of the products will commence immediately.
Bupropion Hydrochloride extended-release tablets (SR), available in 150mg strength, are the generic equivalent of Wellbutrin SR® and are indicated for the treatment of major depressive disorder. Annual sales of brand and generic Wellbutrin SR® were US$ 498 million for the 12 months ending December 2007 according to IMS Health data. Bupropion Hydrochloride extended-release tablets (SR), available in 150mg strength, are the generic equivalent of Zyban® and are indicated as an aid to smoking cessation treatment. Annual sales of brand and generic Zyban® were US$ 12 million for the 12 months ending December 2007 according to IMS Health data.
Actavis Bulgaria launches record 29 products in 1Q Actavis Bulgaria launched 29 new products during the first three months of the year. The company plans to launch a total of 43 new products in Bulgaria during 2008. The newly launched products include Fosinopril HCT (cardiovascular) and Lisinopril HCT (cardiovascular), both of which were first to market in Bulgaria; Irinotecan (oncology), which Actavis has also recently marketed in the United States; Sertraline (antidepressant) and Bicalutamide (oncology). Of the 29 products, 23 are nutritional supplements and products from the Decubal cosmetics line.
Actavis Romania says goodbye to dry skin Decubal, Actavis' complete range dedicated exclusively to dry skin, has been officially launched in Romania. The range comprises 17 products. The products, based on long-term research and clinic testing, are dedicated to cleaning and caring for the face, body, scalp and hair.
No comments:
Post a Comment